Anthem Competitors

Anthem (NYSE:ANTM) and Pfizer (NYSE:PFE) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations and dividends.

Profitability

This table compares Anthem and Pfizer's net margins, return on equity and return on assets.

Dividends

Anthem pays an annual dividend of $4.52 per share and has a dividend yield of 1.2%. Pfizer pays an annual dividend of $1.56 per share and has a dividend yield of 4.0%. Anthem pays out 23.3% of its earnings in the form of a dividend. Pfizer pays out 52.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Anthem has raised its dividend for 1 consecutive years and Pfizer has raised its dividend for 1 consecutive years.

Institutional & Insider Ownership

89.4% of Anthem shares are owned by institutional investors. Comparatively, 67.4% of Pfizer shares are owned by institutional investors. 0.2% of Anthem shares are owned by company insiders. Comparatively, 0.1% of Pfizer shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings for Anthem and Pfizer, as reported by MarketBeat.

Anthem currently has a consensus target price of $365.60, indicating a potential downside of 4.26%. Pfizer has a consensus target price of $38.5714, indicating a potential downside of 1.17%. Given Pfizer's higher probable upside, analysts clearly believe Pfizer is more favorable than Anthem.

Risk & Volatility

Anthem has a beta of 1, suggesting that its stock price has a similar volatility profile to the S&P 500.Comparatively, Pfizer has a beta of 0.7, suggesting that its stock price is 30% less volatile than the S&P 500.

Valuation & Earnings

This table compares Anthem and Pfizer's revenue, earnings per share (EPS) and valuation.

Pfizer has lower revenue, but higher earnings than Anthem. Pfizer is trading at a lower price-to-earnings ratio than Anthem, indicating that it is currently the more affordable of the two stocks.

Anthem (NYSE:ANTM) and Abbott Laboratories (NYSE:ABT) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, profitability, earnings and analyst recommendations.

Profitability

This table compares Anthem and Abbott Laboratories' net margins, return on equity and return on assets.

Dividends

Anthem pays an annual dividend of $4.52 per share and has a dividend yield of 1.2%. Abbott Laboratories pays an annual dividend of $1.80 per share and has a dividend yield of 1.5%. Anthem pays out 23.3% of its earnings in the form of a dividend. Abbott Laboratories pays out 55.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Anthem has increased its dividend for 1 consecutive years and Abbott Laboratories has increased its dividend for 49 consecutive years. Abbott Laboratories is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Valuation and Earnings

This table compares Anthem and Abbott Laboratories' top-line revenue, earnings per share (EPS) and valuation.

Anthem has higher revenue and earnings than Abbott Laboratories. Anthem is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings for Anthem and Abbott Laboratories, as provided by MarketBeat.

Anthem currently has a consensus target price of $365.60, indicating a potential downside of 4.26%. Abbott Laboratories has a consensus target price of $124.0588, indicating a potential upside of 3.38%. Given Abbott Laboratories' higher probable upside, analysts plainly believe Abbott Laboratories is more favorable than Anthem.

Volatility & Risk

Anthem has a beta of 1, suggesting that its share price has a similar volatility profile to the S&P 500.Comparatively, Abbott Laboratories has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500.

Institutional and Insider Ownership

89.4% of Anthem shares are held by institutional investors. Comparatively, 72.6% of Abbott Laboratories shares are held by institutional investors. 0.2% of Anthem shares are held by company insiders. Comparatively, 1.7% of Abbott Laboratories shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Anthem beats Abbott Laboratories on 9 of the 17 factors compared between the two stocks.

Novartis (NYSE:NVS) and Anthem (NYSE:ANTM) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, valuation, analyst recommendations and institutional ownership.

Dividends

Novartis pays an annual dividend of $2.08 per share and has a dividend yield of 2.4%. Anthem pays an annual dividend of $4.52 per share and has a dividend yield of 1.2%. Novartis pays out 39.7% of its earnings in the form of a dividend. Anthem pays out 23.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Novartis has increased its dividend for 1 consecutive years and Anthem has increased its dividend for 1 consecutive years.

Institutional and Insider Ownership

9.9% of Novartis shares are held by institutional investors. Comparatively, 89.4% of Anthem shares are held by institutional investors. 0.0% of Novartis shares are held by company insiders. Comparatively, 0.2% of Anthem shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and price targets for Novartis and Anthem, as reported by MarketBeat.

Novartis presently has a consensus price target of $108.50, indicating a potential upside of 23.53%. Anthem has a consensus price target of $365.60, indicating a potential downside of 4.26%. Given Novartis' higher possible upside, analysts clearly believe Novartis is more favorable than Anthem.

Profitability

This table compares Novartis and Anthem's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Novartis and Anthem's revenue, earnings per share (EPS) and valuation.

Novartis has higher earnings, but lower revenue than Anthem. Novartis is trading at a lower price-to-earnings ratio than Anthem, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Novartis has a beta of 0.59, indicating that its share price is 41% less volatile than the S&P 500. Comparatively, Anthem has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500.

Merck & Co., Inc. (NYSE:MRK) and Anthem (NYSE:ANTM) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, earnings, risk and analyst recommendations.

Insider & Institutional Ownership

72.9% of Merck & Co., Inc. shares are owned by institutional investors. Comparatively, 89.4% of Anthem shares are owned by institutional investors. 0.3% of Merck & Co., Inc. shares are owned by insiders. Comparatively, 0.2% of Anthem shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Merck & Co., Inc. and Anthem's gross revenue, earnings per share and valuation.

Merck & Co., Inc. has higher earnings, but lower revenue than Anthem. Merck & Co., Inc. is trading at a lower price-to-earnings ratio than Anthem, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Merck & Co., Inc. and Anthem's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent recommendations and price targets for Merck & Co., Inc. and Anthem, as provided by MarketBeat.com.

Merck & Co., Inc. currently has a consensus target price of $96.2727, suggesting a potential upside of 22.53%. Anthem has a consensus target price of $365.60, suggesting a potential downside of 4.26%. Given Merck & Co., Inc.'s stronger consensus rating and higher possible upside, equities research analysts clearly believe Merck & Co., Inc. is more favorable than Anthem.

Dividends

Merck & Co., Inc. pays an annual dividend of $2.60 per share and has a dividend yield of 3.3%. Anthem pays an annual dividend of $4.52 per share and has a dividend yield of 1.2%. Merck & Co., Inc. pays out 50.1% of its earnings in the form of a dividend. Anthem pays out 23.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Merck & Co., Inc. has increased its dividend for 1 consecutive years and Anthem has increased its dividend for 1 consecutive years.

Volatility and Risk

Merck & Co., Inc. has a beta of 0.43, indicating that its stock price is 57% less volatile than the S&P 500. Comparatively, Anthem has a beta of 1, indicating that its stock price has a similar volatility profile to the S&P 500.

Summary

Merck & Co., Inc. beats Anthem on 9 of the 16 factors compared between the two stocks.

Anthem (NYSE:ANTM) and AbbVie (NYSE:ABBV) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, institutional ownership, risk, profitability, valuation and analyst recommendations.

Volatility & Risk

Anthem has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500.Comparatively, AbbVie has a beta of 0.84, indicating that its share price is 16% less volatile than the S&P 500.

Dividends

Anthem pays an annual dividend of $4.52 per share and has a dividend yield of 1.2%. AbbVie pays an annual dividend of $5.20 per share and has a dividend yield of 4.8%. Anthem pays out 23.3% of its earnings in the form of a dividend. AbbVie pays out 58.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Anthem has raised its dividend for 1 consecutive years and AbbVie has raised its dividend for 49 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Institutional & Insider Ownership

89.4% of Anthem shares are owned by institutional investors. Comparatively, 67.5% of AbbVie shares are owned by institutional investors. 0.2% of Anthem shares are owned by company insiders. Comparatively, 0.1% of AbbVie shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Anthem and AbbVie's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current recommendations for Anthem and AbbVie, as reported by MarketBeat.

Anthem currently has a consensus price target of $365.60, suggesting a potential downside of 4.26%. AbbVie has a consensus price target of $115.75, suggesting a potential upside of 6.16%. Given AbbVie's higher possible upside, analysts clearly believe AbbVie is more favorable than Anthem.

Earnings & Valuation

This table compares Anthem and AbbVie's gross revenue, earnings per share and valuation.

AbbVie has lower revenue, but higher earnings than Anthem. AbbVie is trading at a lower price-to-earnings ratio than Anthem, indicating that it is currently the more affordable of the two stocks.

Summary

AbbVie beats Anthem on 9 of the 17 factors compared between the two stocks.

Thermo Fisher Scientific (NYSE:TMO) and Anthem (NYSE:ANTM) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, risk, valuation, earnings and dividends.

Volatility & Risk

Thermo Fisher Scientific has a beta of 0.85, meaning that its stock price is 15% less volatile than the S&P 500. Comparatively, Anthem has a beta of 1, meaning that its stock price has a similar volatility profile to the S&P 500.

Dividends

Thermo Fisher Scientific pays an annual dividend of $1.04 per share and has a dividend yield of 0.2%. Anthem pays an annual dividend of $4.52 per share and has a dividend yield of 1.2%. Thermo Fisher Scientific pays out 8.4% of its earnings in the form of a dividend. Anthem pays out 23.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Thermo Fisher Scientific has increased its dividend for 3 consecutive years and Anthem has increased its dividend for 1 consecutive years.

Institutional & Insider Ownership

87.2% of Thermo Fisher Scientific shares are owned by institutional investors. Comparatively, 89.4% of Anthem shares are owned by institutional investors. 0.4% of Thermo Fisher Scientific shares are owned by company insiders. Comparatively, 0.2% of Anthem shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Thermo Fisher Scientific and Anthem's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of current ratings for Thermo Fisher Scientific and Anthem, as reported by MarketBeat.com.

Thermo Fisher Scientific currently has a consensus target price of $527.05, suggesting a potential upside of 9.26%. Anthem has a consensus target price of $365.60, suggesting a potential downside of 4.26%. Given Thermo Fisher Scientific's stronger consensus rating and higher probable upside, equities analysts plainly believe Thermo Fisher Scientific is more favorable than Anthem.

Valuation & Earnings

This table compares Thermo Fisher Scientific and Anthem's gross revenue, earnings per share and valuation.

Anthem has higher revenue and earnings than Thermo Fisher Scientific. Anthem is trading at a lower price-to-earnings ratio than Thermo Fisher Scientific, indicating that it is currently the more affordable of the two stocks.

Summary

Thermo Fisher Scientific beats Anthem on 11 of the 17 factors compared between the two stocks.